Sales of Amgen's Blincyto have grown slowly since it was first introduced a decade ago, but have started to gather momentum thanks to expanded use in acute lymphoblastic leukaemia (ALL), which ...

Cullinan Therapeutics (NASDAQ:CGEM) drew Wall Street's attention last week as William Blair touted the stock after peer-reviewed data for Amgen's (NASDAQ:AMGN) leukemia therapy, Blincyto ...

Amgen’s Blincyto (blinatumomab) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat certain cases of acute lymphoblastic leukaemia (ALL). The health ...

Amgen’s Blincyto (blinatumomab) has been approved by the European Commission (EC) to treat certain acute lymphoblastic leukaemia (ALL) patients earlier in their treatment journey. Blincyto monotherapy ...

Amgen’s Blincyto has been granted a full European licence in a form of blood cancer following data showing the drug almost doubled overall survival time compared with standard therapy.